-
1.发明公开SALT AND POLYMORPH OF PYRAZOLOPYRIMIDINONE COMPOUND AND DRUG COMPOSITION, PREPARATION METHOD AND USE THEREOF 有权盐和多晶型吡唑并嘧啶ONE AND活性物质，其制造方法相同，它们的用途
公开(公告)号：EP2746284A1
公开(公告)日：2014-06-25
申请号：EP12823704.7
申请日：2012-08-14
申请人： Topharman Shanghai Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Topharman Shandong Co., Ltd.
发明人： LI, Jianfeng , TIAN, Guanghui , WANG, Zhen , SUO, Jin , JIANG, Xiangrui , LIU, Zheng , YANG, Xiaojun , XIE, Zhu , ZHAO, Xianguo , ZHU, Weiliang , JIANG, Hualiang , SHEN, Jingshan
IPC分类号： C07D487/04 , A61K31/519 , A61P15/10 , A61P9/12 , A61P15/00 , A61P15/06 , A61P13/08 , A61P13/10 , A61P13/00 , A61P9/10 , A61P9/04 , A61P13/12 , A61P29/00 , A61P11/00 , A61P11/06 , A61P11/02 , A61P37/08 , A61P27/06 , A61P1/00 , A61P9/00 , A61P25/00
CPC分类号： C07D487/04 , C07B2200/13
摘要： The present invention relates to new salts of pyrazolopyrimidinone represented by formula (I), and pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystallization, anhydrous, or amorphous form thereof, the pharmaceutical compositions, and a pharmaceutical unit dosage form containing the same, wherein x represents organic or inorganic acids, preferable maleic acid, succinic acid, methanesulfonic acid, hydrochloric acid, etc. The invention further relates to co-crystals or complexes of compounds of pyrazolopyrimidinone and pharmaceutical compositions containing the same. The present invention also relates to a process for the preparation, use thereof and pharmaceutical preparation containing the salts or crystalline forms.
摘要翻译： 本发明涉及由式（I），和药学上可接受的多晶型物，溶剂化物，水合物，脱水物，共结晶，无水，或其无定形形式，所述药物组合物和药物单位剂量形式含在代表pyrazolopyrimidinones的新的盐 同样，worin X darstellt有机或无机酸，马来酸优选，琥珀酸，甲磺酸，盐酸，等等。本发明还涉及pyrazolopyrimidinones和含有相同的药物组合物的化合物的共结晶或络合物。 因此，本发明涉及一种用于制备，使用其和含有盐或结晶形式的药物制剂。
-
2.发明公开GLECHOMA LONGITUBE EXTRACT, PREPARATION METHOD FOR SAME, AND USE THEREOF IN SUGAR REDUCTION, WEIGHT LOSS, AND LIPID REDUCTION 审中-公开GLECHOMA LONGTUBE提取物及其制备方法及其在减少糖，重量损失和脂质减少中的应用
公开(公告)号：EP3120847A1
公开(公告)日：2017-01-25
申请号：EP15765481.5
申请日：2015-03-17
申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Nanjing Pailexing Pharmaceutical Technology Ltd.
发明人： ZHU, Weiliang , WANG, Heyao , ZHANG, Yong , SUN, Peng , LI, Bo , XU, Zhijian , JIANG, Hualiang , CHEN, Kaixian
CPC分类号： A61K31/7048 , A61K36/53 , A61K2236/30 , A61K2236/53
摘要： Disclosed is a Glechoma longituba (Nakai) Kupr . extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.
摘要翻译： 披露是一种Glechoma longituba（Nakai）Kupr。 提取物，特别是化合物I和II，其制备方法，以及其在制备用于血糖降低，血脂降低，体重减轻和肾脏疾病治疗的药物中的用途或用于治疗所述疾病的方法， 含有提取物。
-
3.发明公开PHENYL PYRIMIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF 有权PHENYLPYRIMIDONVERBINDUNGEN，PHARMAZEUTISCHE ZUSAMMENSETZUNGEN，HERSTELLUNGSVERFAHREN UND ANWENDUNGEN DAVON
公开(公告)号：EP2383262A1
公开(公告)日：2011-11-02
申请号：EP09831388.5
申请日：2009-12-10
申请人： Topharman Shanghai Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Topharman Shandong Co., Ltd.
发明人： LIU, Zheng , LI, Jianfeng , YANG, Xiaojun , WANG, Zhen , ZHANG, Jinfeng , ZHU, Yi , TIAN, Guanghui , JIN, Qing , SHEN, Jingkang , ZHU, Weiliang , JIANG, Hualiang , SHEN, Jingshan
IPC分类号： C07D239/36 , A61K31/505 , A61P15/10
CPC分类号： A61K31/505 , C07D239/36 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07H15/26
摘要： The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof; and to the pharmaceutical composition as well as the preparation method of the said compounds. The said compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.
摘要翻译： 本发明涉及一类苯基嘧啶酮化合物，药物组合物，其制备方法及用途。 更具体地，本发明涉及一种下式I的苯基嘧啶酮化合物，其药学上可接受的盐或溶剂合物; 和药物组合物以及所述化合物的制备方法。 所述根据本发明的式I化合物可有效抑制V型磷酸二酯酶（PDE5），因此可用于治疗各种血管疾病，如男性勃起功能障碍，肺动脉高压等。
-
4.发明公开
公开(公告)号：EP3954692A1
公开(公告)日：2022-02-16
申请号：EP20787011.4
申请日：2020-03-30
发明人： LI, Bo , LIU, Peng , SUN, Haiguo , XI, Mengyu , XU, Zhijian , ZHANG, Yong , ZHU, Weiliang
IPC分类号： C07D498/04 , C07D213/64
摘要： The present invention relates to a method for modifying or marking an amino group in a molecule, wherein the amino group in the molecule is modified or marked with zolinium(s) shown in the following formula 1, wherein the molecule comprises amino acid ester, aminoamide, or peptide/protein. The method has advantages of economy and site selectivity, and has huge potential application value in the field such as pharmaceutical molecular synthesis, probe molecule and diagnostic marker reagent development.
-
5.发明授权SALT AND POLYMORPH OF PYRAZOLOPYRIMIDINONE COMPOUND AND DRUG COMPOSITION, PREPARATION METHOD AND USE THEREOF 有权盐和多晶型吡唑并嘧啶和活性物质，其制造方法相同，它们的用途
公开(公告)号：EP2746284B1
公开(公告)日：2017-04-12
申请号：EP12823704.7
申请日：2012-08-14
申请人： Topharman Shanghai Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Topharman Shandong Co., Ltd.
发明人： LI, Jianfeng , TIAN, Guanghui , WANG, Zhen , SUO, Jin , JIANG, Xiangrui , LIU, Zheng , YANG, Xiaojun , XIE, Zhu , ZHAO, Xianguo , ZHU, Weiliang , JIANG, Hualiang , SHEN, Jingshan
IPC分类号： C07D487/04 , A61K31/519 , A61P15/10 , A61P9/12 , A61P15/00 , A61P15/06 , A61P13/08 , A61P13/10 , A61P13/00 , A61P9/10 , A61P9/04 , A61P13/12 , A61P29/00 , A61P11/00 , A61P11/06 , A61P11/02 , A61P37/08 , A61P27/06 , A61P1/00 , A61P9/00 , A61P25/00
CPC分类号： C07D487/04 , C07B2200/13
摘要： The present invention relates to new salts of pyrazolopyrimidinone represented by formula (I), and pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystallization, anhydrous, or amorphous form thereof, the pharmaceutical compositions, and a pharmaceutical unit dosage form containing the same, wherein x represents organic or inorganic acids, preferable maleic acid, succinic acid, methanesulfonic acid, hydrochloric acid, etc. The invention further relates to co-crystals or complexes of compounds of pyrazolopyrimidinone and pharmaceutical compositions containing the same. The present invention also relates to a process for the preparation, use thereof and pharmaceutical preparation containing the salts or crystalline forms.
-
6.发明授权PHENYL PYRIMIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF 有权PHENYLPYRIMIDONVERBINDUNGEN，药物组合物，方法和应用
公开(公告)号：EP2383262B1
公开(公告)日：2016-07-06
申请号：EP09831388.5
申请日：2009-12-10
申请人： Topharman Shanghai Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Topharman Shandong Co., Ltd.
发明人： LIU, Zheng , LI, Jianfeng , YANG, Xiaojun , WANG, Zhen , ZHANG, Jinfeng , ZHU, Yi , TIAN, Guanghui , JIN, Qing , SHEN, Jingkang , ZHU, Weiliang , JIANG, Hualiang , SHEN, Jingshan
IPC分类号： C07D239/36 , A61K31/505 , A61P15/10
CPC分类号： A61K31/505 , C07D239/36 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07H15/26
-
7.发明公开
公开(公告)号：EP1968569A1
公开(公告)日：2008-09-17
申请号：EP06835982.7
申请日：2006-12-15
发明人： PUAH, Chum Mok , ZHU, Weiliang , LI, Jian , CHEN, Lili , LUO, Cheng , CHEN, Gang , ZUO, Zhili , LUO, Xiaomin , SHEN, Xu , CHEN, Kaixian , JIANG, Hualiang
CPC分类号： A61K31/35 , C07D311/30 , C07D407/04 , C07H17/06
摘要： The invention relates to pharmaceutical compositions comprising benzopyranone derivatives for the treatment of Severe Acute Respiratory Syndrome (SARS).
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.023 秒)
